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Abstract
Background: The approach to surveillance of Lyme borreliosis varies between countries, depending on the purpose
of the surveillance system and the notification criteria used, which prevents direct comparison of national data. In
Norway, Lyme borreliosis is notifiable to the Surveillance System for Communicable Diseases (MSIS). The current
notification criteria include a combination of clinical and laboratory results for borrelia infection (excluding Erythema
migrans) but there are indications that these criteria are not followed consistently by clinicians and by laboratories.
Therefore, an evaluation of Lyme borreliosis surveillance in Norway was conducted to describe the purpose of the
system and to assess the suitability of the current notification criteria in order to identify areas for improvement.
Methods: The CDC Guidelines for Evaluation of Surveillance Systems were used to develop the assessment of the data
quality, representativeness and acceptability of MSIS for surveillance of Lyme borreliosis. Data quality was assessed
through a review of data from 1996 to 2013 in MSIS and a linkage of MSIS data from 2008 to 2012 with data from the
Norwegian Patient Registry (NPR). Representativeness and acceptability were assessed through a survey sent to 23
diagnostic laboratories.
Results: Completeness of key variables for cases reported to MSIS was high, except for geographical location of
exposureThe NPR-MSIS linkage identified 1047 cases in both registries, while 363 were only reported to MSIS and 3914
were only recorded in NPR. A higher proportion of cases found in both registries were recorded as neuroborreliosis in
MSIS (84.4 %) than those cases found only in MSIS (20.1 %). The trend (average yearly increase or decrease in reported
cases) of neuroborreliosis in MSIS was not significantly different from the trend for all other clinical manifestations
recorded in MSIS in negative binomial regression (p = 0.3). The 16 surveyed laboratories (response proportion 70 %)
indicated differences in testing practices and low acceptability of the notification criteria.
Conclusions: Given the challenges associated with diagnosing Lyme borreliosis, the selected notification criteria
should be closely linked with the purpose of the surveillance system. Restricting reportable Lyme borreliosis to
neuroborreliosis may increase validity, while a more sensitive case definition (potentially including erythema migrans)
may better reflect the true burden of disease. We recommend revising the current notification criteria in Norway to
ensure that they are unambiguous for clinicians and laboratories.
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Background
Lyme borreliosis (LB), caused by the spirochete Borrelia
burgdorferi sensu lato, is the most commonly reported
tickborne infection in Norway [1]. LB has many different
clinical presentations that include dermatological, rheu-
matologic, cardiac and neurological symptoms [2]. Lo-
calized infection is most often characterized by erythema
migrans, a rash that often occurs at the site of a tick bite
between 3 and 30 days after being bitten. The infection
may disseminate weeks to months following exposure
and can result in a range of manifestations, including
multiple erythema migrans skin lesions, Lyme neurobor-
reliosis, Lyme arthritis, borrelial lymphocytoma, acroder-
matitis chronica atrophicans (ACA) and Lyme carditis [3].
IgM antibodies may be detectable 1 to 2 weeks after tick
bite, typically peak during the third to sixth week after
onset and demonstrate a gradual decline over several
months, while IgG can be detected as early as 2 weeks
after onset of disease and can remain at significant levels
for many years after onset and after cleared infection [4].
Although diagnosis of the most common clinical presen-
tations of LB is generally straightforward in combination
with laboratory results, there is a risk of misdiagnosis for
cases with ambiguous clinical presentation or false positive
or inconclusive test results. This is particularly relevant in
areas with a high prevalence of seropositivity, which can
influence pre-test probability of a positive result [2]. The
possibility of false positives due to the high testing rate in
Norway of up to 60,000 people per year cannot be dis-
counted, despite a high test specificity. Studies have found
that 18 % of healthy blood donors from southern Norway
[5] and up to 10 % in Western Norway [6] are seropositive
for Borrelia burgdorferi IgG antibodies. Due to the com-
plexities associated with diagnosis of LB, surveillance of
the disease is inherently challenging. The reporting systems
and notification criteria used for surveillance in different
countries vary and the sources of data are diverse, with
physician reports, laboratory reports, hospital records,
sentinel surveillance sites, and seroprevalence studies used
as sources of surveillance data [7–9]. LB has been notifi-
able to the Norwegian Surveillance System for Communic-
able Diseases (MSIS), based on a combination of clinical
and laboratory criteria, since 1995. In Norway, the current
notification criterium for LB is:
A clinically compatible case (not erythema migrans
only) with laboratory confirmation of Borrelia
burgdorferi by:
– isolation or nucleic acid test
– antibodies (IgM in serum or cerebrospinal fluid
(CSF), or IgG in CSF produced intrathecally or with
a high concentration in serum).
Early localized disease (erythema migrans only) is not
notifiable. Multiple erythema migrans is considered
disseminated disease and is notifiable.
From 1995 to 2013, a total of 4148 cases of LB were
reported through MSIS, corresponding to an average
annual incidence of 4.7 cases per 100,000 population,
ranging from 2.3 in 2002 to 7.3 in 2008 (Fig. 1). How-
ever, the incidence varied greatly by geographical area
throughout Norway. The vector for Borrelia burgdorferi,
Ixodes ricinus, is found primarily in coastal areas,
stretching from the Oslofjord north to Helgelandskysten.
However, it is increasingly being found further inland, at
more northern latitudes and at higher altitudes [10].
It is suspected that the Norwegian notification cri-
teria are interpreted inconsistently by laboratories and
clinicians in Norway. The results of national proficiency
testing in 2012 showed that interpretation of diagnostic
test results for LB is not uniform among laboratories
[11]. Therefore, an evaluation was conducted to assess
the performance of MSIS for the surveillance of LB in
order to provide recommendations for improvement of
the surveillance system. In particular, the results of the
evaluation were compiled to assess the suitability of the
Fig. 1 Incidence rate of Lyme borreliosis reported via MSIS per 100 000 population, Norway, 1995–2013
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current notification criteria for surveillance of LB in
Norway. Using the Centers for Disease Control and
Prevention (CDC) Updated Guidelines for Evaluating
Public Health Surveillance Systems [12], the following
three attributes of MSIS were selected for evaluation:
data quality (which includes completeness), representa-
tiveness, and acceptability.
Methods
Lyme borreliosis surveillance in Norway
Lyme borreliosis in the Norwegian Surveillance System for
Communicable Diseases (MSIS)
MSIS was implemented nationwide in 1979 and is ad-
ministered by the Norwegian Institute of Public Health
(NIPH). The stated objective of MSIS is to enable sur-
veillance of infectious diseases in humans in Norway
through the ongoing and systematic collection, analysis,
interpretation and reporting of data on the incidence of
infectious diseases [13]. The data in MSIS is collected
in order to 1) describe the incidence of infectious dis-
eases over time, including the geographic distribution
and demographic characteristics; 2) detect and contrib-
ute to the investigation of outbreaks of infectious dis-
eases; 3) advise the public, healthcare professionals and
public health authorities on infection control measures;
4) evaluate the effects of infection control measures;
and 5) conduct, promote and provide a basis for re-
search on infectious disease epidemiology and causes of
infectious disease. Beyond the general objectives for
MSIS, specific objectives for the surveillance of LB in
Norway are not defined.
Notifiable diseases in Norway are currently divided
into three groups [13]. Group A diseases, which
includes LB, are notifiable to the Department of Infec-
tious Disease Surveillance at the NIPH by clinicians
and medical microbiological laboratories with complete
patient information. Cases of LB were notified sporad-
ically to MSIS from 1983 [1]. Since 1991, LB has been
nominally notifiable. In the early years of notification,
all manifestations of LB were notifiable, including
erythema migrans. The case definition was revised with
the implementation of the Infection Disease Control
Act in 1995, after which only disseminated and chronic
manifestations remained notifiable (specifically exclud-
ing cases with only erythema migrans).
Diagnosis of Lyme borreliosis
Three types of tests are in use in Norway to detect borre-
lia: ELISA/chemiluminescence assay and Western blot/
line blot for antibody detection, and PCR for detection of
genetic material. Line blot testing is available in larger
laboratories, but is not required for confirmation of ELISA
results. PCR is conducted at three laboratories, including
the National Reference Laboratory for borreliosis at
Sørlandet Hospital. In Norway it is recommended to use
ELISA with VlsE/C6 peptide, rather than the two tired
principle recommended in the USA (enzyme immuno-
assay or immunofluorescence assay, followed by Western
Blot). Testing for LB antibodies is most often performed
on serum and/or CSF, while PCR for detection of genetic
material is done on synovial fluid for cases of Lyme arth-
ritis and on biopsies from skin lesions. Antibody levels are
reported as either qualitative values (high, low or border-
line value) or as quantitative values, such as a percent of
the cut off value or in units defined by the manufacturer
of the assay.
Data flow
When a patient with a suspected LB seeks healthcare, the
clinician sends the relevant specimens to a laboratory
(Fig. 2). When a laboratory result indicates LB and sub-
mitted clinical information supports notifiable Lyme bor-
reliosis, the laboratory should notify both the requesting
clinician and MSIS. For each notifiable case of LB, clini-
cians are required to submit a standardised paper form to
MSIS by mail. The same form is used for all Group A
diseases. Clinical symptoms are reported in free text in the
notification form. The clinician is also required to send
the notification to the Municipal Medical Officer in the
patient’s municipality of residence. Laboratory results for
LB are not submitted to NIPH using a standard template.
When clinical and laboratory notifications are received
by the NIPH, the information is manually entered in
the MSIS database. The free text clinical information
provided by the reporting clinician is used to group
reported cases into one of the following categories for
clinical presentation in MSIS neurological symptoms
with peripheral nervous system manifestation, arthritis,
meningitis/encephalitis, necrotizing fasciitis, ACA, other
or missing. The notifications from laboratories and clini-
cians are linked and registered as one case using the per-
sonal identification number. The source of the notification
(laboratory, clinician or both) is indicated in the MSIS
database.
Evaluation of performance attributes
Three attributes were selected for the evaluation: Data
quality (including completeness), representativeness and
acceptability (Fig. 3). Three methods were used to assess
these attributes: 1) descriptive statistics of data in MSIS,
2) linkage between MSIS and NPR, and 3) a survey of
laboratories.
Data quality
In order to assess the completeness of the data, key vari-
ables for all LB records in MSIS from 1995 to 2013 were
reviewed to determine the percentage of ‘unknown’ and
‘missing’ responses. The key variables selected were:
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Fig. 2 Flow of information from clinicians and laboratories to MSIS
Fig. 3 Selected attributes, data collection methods and indicators for evaluation of the surveillance of Lyme borreliosis in the Norwegian Surveillance
System for Communicable Diseases (MSIS)
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birthdate; personal number; sex; source of report; report-
ing laboratory; testing material; testing method, reason for
testing; clinical symptoms; hospitalization status; outcome;
and geographic location of exposure. Cases are reported
as being exposed in their county of residence, exposed
outside the county of residence or exposed in an unknown
county. All cases with geographic location of exposure
reported as unknown or missing, or location of exposure
reported as Norway but with the county of exposure
either unknown or missing, were categorized as having an
‘unknown county of infection’.
Given the limitations in the available data, it was out-
side the scope of this evaluation to conduct a conclusive
assessment of the validity of the data in MSIS (ie the
proportion of cases in MSIS that are true cases of Lyme
borreliosis). However, it was possible to compare the
registration of Lyme borreliosis cases in two databases
to determine the proportion of cases that appear in both
sources. In order to ascertain the proportion of cases
collected through MSIS that were also registered in the
Norwegian Patient Registry (NPR), all cases of LB noti-
fied to MSIS between 1 January 2008 and 31 December
2012 were linked to cases of LB registered in the NPR.
NPR is administered by the Norwegian Directorate of
Health and contains information on all referrals or treat-
ments of patients to tertiary care facilities and specialists
only. The diagnosis registered in NPR is based on ICD-
10 codes. Codes registered in NPR can be used for dif-
ferential diagnosis and do not necessarily reflect the final
diagnosis. For each entry in NPR, two main diagnoses
and 20 additional diagnoses can be recorded. LB is gen-
erally coded as A69.2 – Lyme disease (Erythema chroni-
cum migrans due to Borrelia burgdorferi), but can also
be coded as M01.2 – Arthritis in Lyme disease. How-
ever, coding can vary by hospital and it is possible that
other codes can be used, particularly for cases of neuro-
borreliosis. In order to identify potentially miscoded
cases of LB, all patients registered with one of the pre-
selected ICD-10 codes between 1 January 2008 and 31
December 2012 were extracted from NPR (Table 1).
Cases of LB in MSIS and patients in NPR with one of
the defined ICD-10 codes were linked using personal
identification numbers, a unique identifier given to all
Norwegian residents, using serial numbers to prevent
identification of patients.
Descriptive statistics were produced in order to examine
the proportion of neuroborreliosis cases of all LB cases
reported to MSIS annually and to identify whether the
same pattern was reflected in cases with other clinical
manifestations. Cases registered in MSIS with neurological
symptoms with peripheral nervous system manifest-
ation or meningitis/encephalitis were considered neuro-
borreliosis cases, based on the information provided by
the reporting clinician in free-text fields. All other
clinical manifestations indicated by reporting clinicians
were categorized as “other”. The proportion of cases
reported to both MSIS and NPR was compared to the
proportion of cases reported as neuroborreliosis to
MSIS only.
Representativeness and acceptability
Representativeness was evaluated through self-administered
questionnaires sent to all public and private diagnostic
microbiology laboratories in Norway (n = 23). Respon-
dents were asked to specify the kit used for diagnosis of
borreliosis, how IgG and IgM levels are measured, if
thresholds for positive IgG and IgM results are defined,
and if standard text is used to report results. The ques-
tionnaire was distributed electronically by email using
Questback on 13 May 2014. Several questions in the
survey distributed to laboratories examined perceptions
regarding the current notification criteria and accept-
ability of the existing surveillance system. Respondents
were asked to indicate whether they think the notifica-
tion criteria for LB are clear, if the diagnostic capacity
for LB in Norway is satisfactory, if there is a need for
harmonization of diagnostics by using fewer different
kits, if there is a need for harmonization of standard
text for reporting serology results, and if there was a
need for having a kit-independent control.
Data analysis
Descriptive statistics of data from MSIS and from the
laboratory survey were calculated in Excel. Population
data at the municipal level used to calculate annual inci-
dence rates were acquired from Statistics Norway. The
trend of neuroborreliosis cases versus all other clinical
manifestations from 1995 to 2013 and 2004 to 2013 was
tested using negative binomial regression. Analysis of
Table 1 ICD-10 codes pre-selected for possible Lyme borreliosis
in the Norwegian Patient Registry
Lyme borreliosis:
• A69.2 – Lyme disease (Erythema chronicum migrans due to
Borrelia burgdorferi)
• M01.2 – Arthritis in Lyme disease
Possible Lyme borreliosis:
• G04.2 - Bacterial meningoencephalitis and meningomyelitis,
not elsewhere classified
• G04.8 – Other encephalitis, myelitis and encephalomyelitis
(Postinfectious encephalitis and encephalomyelitis NOS)
• G51.0 – Bell palsy (facial palsy)
• G51.8 – Other disorders of facial nerve
• G51.9 – Disorder of facial nerve, unspecified
• G63.0 – Polyneuropathy in infectious and parasitic diseases
classified elsewhere
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the linkage of MSIS and NPR and binomial regression
for trend in neuroborreliosis was done in Stata v14.
Ethical approval for the NPR-MSIS study was pro-
vided by the Regional Ethics Committee for South East
Norway. Written consent was not required from the
study population.
Results
Evaluation of performance attributes
Data quality
Of the 4148 cases of LB reported to MSIS between 1995
and 2013, 85.9 % (n = 3 565) were notified by both a
clinician and a laboratory. For 161 cases (3.8 %), only
clinical notification was received, while for 421 cases
(10.2 %) only laboratory notification was received. The
proportion of cases reported by both clinicians and la-
boratories varied with a low of 68.2 % in 2005 to a high
of 97.7 % in 2008. With the exception of two cases, all
cases reported exclusively by a clinician occurred in
2006 or earlier. From 2006, only cases with a laboratory
notification, or notification from both a clinician and the
laboratory, were kept in MSIS. Those cases for which
only a clinical notification was received were removed
from MSIS if no laboratory results were received. It is
unknown how many notifications from clinicians only
were received after 2006.
Completeness of the key variables selected for surveil-
lance of borreliosis varied from 0 % missing or unknown
to more than 40 % missing or unknown. The most
complete variables overall (when considering both
‘empty’ and ‘unknown’ as incomplete) were birthdate,
personal number, sex and testing laboratory, all with
close to 100 % completeness. The variables that were
least complete overall were outcome of illness and place
of infection, with 43.8 and 35.3 % ‘empty’ or ‘unknown’,
respectively. For all variables, the proportion ‘empty’ was
larger than the proportion ‘unknown’, with the exception
of outcome and geographic location of exposure. When
compared to the completeness for all Group A diseases
in 2012, LB had a higher level of completeness for all
variables with the exception of geographic location of
exposure, for which completeness was 89.5 % for LB
compared to 91.0 % for all diseases.
The most commonly coded clinical manifestations in
MSIS were neurological symptoms with peripheral ner-
vous system manifestation (62.7 %, n = 2602), arthritis
(12.7 %, n = 528 cases), and meningitis/encephalitis
(2.2 %, n = 93 cases). Necrotizing fasciitis was reported
for one case, while 660 cases (15.9 %) were categorized
as “other”. Clinical manifestation was unknown for 47
cases (1.1 %) and missing for 216 cases (5.2 %). The pro-
portion of cases with either missing or unknown clinical
manifestation ranged from 0 % in 1997 to over 13 % in
2013, almost all due to missing reports from clinicians.
Of all cases, 30 % were reported from the National Ref-
erence Laboratory for LB, while 36 % of cases of LB that
were reported with non-neurological manifestations
were reported from the National Reference Laboratory.
Between 1 January 2008 and 31 December 2012, 1410
cases of LB were reported to MSIS and 13,051 patients
were reported to NPR with an ICD-10 code for LB
(A69.2 or M01.2) or an ICD-10 that was pre-selected as
possible LB (G04.2, G04.8, G51.0, G51.8, G51.9 or
G63.0). Of these, 4713 patients had LB recorded as the
main diagnosis, 883 patients had LB recorded as an
additional diagnosis, and 7430 patients were assigned
an ICD-10 code pre-selected for possible LB (but not
codes A69.2 or M01.2). A successful link using the per-
sonal number could be made for 1047 cases in regis-
tered in both MSIS and NPR (Fig. 4). Five cases in
MSIS were missing the personal identification number
and were excluded from further analysis. Of the
remaining 358 cases in MSIS, 347 were found in NPR
but did not have any activity reported or were reported
with ICD-10 codes other than those included in the
linkage. For 11 cases in MSIS, the personal number was
not found in NPR. However, these cases were all re-
ported from general practitioners, who do not report to
NPR. Over 74 % of LB cases (n = 1047) reported to
MSIS could be found in NPR with an LB ICD-10 diag-
nosis code. This constitutes 22 % of patients registered
in NPR with LB as the main diagnosis (1047/4713), or
8 % of the patients with any LB ICD-10 code in NPR
(1047/13,051). For the 25 LB cases reported to MSIS
and registered in NPR with a possible LB diagnosis
code, 19 cases were registered with ICD-10 code G51.0
- Bell palsy (facial palsy). Over 38 % of cases registered
in both NPR and MSIS were under the age of 19, com-
pared to 15 % in NPR only and 26 % in MSIS only.
More than 36 % of cases in MSIS only were over
60 years compared to 25 % in NPR/MSIS and 30 % in
NPR only.
Between 1995 and 2013, the proportion of cases re-
corded as neuroborreliosis in MSIS (neurological symp-
toms with peripheral nervous system manifestation or
meningitis/encephalitis) ranged from 49.6 % in 1995 to
64.4 % in 2006, with an overall average of 64.4 %. Using
all relevant available data from 1995 to 2013, the trend
(average yearly increase/decrease over this time period)
of neuroborreliosis cases versus all other recorded clin-
ical manifestations was not significantly different in
negative binomial regression (p = 0.261). From visually
observing the data, differing trends appeared to occur
from 2004, so a post-hoc analysis was undertaken: From
2004 to 2013, the trend of neuroborreliosis cases versus
all other clinical manifestations was still not significantly
different in negative binomial regression (p = 0.136),
however, the p-value did numerically decrease while the
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number of data was reduced. Between 2008 and 2012,
more cases reported in MSIS and NPR were registered
as neuroborreliosis (84.4 %) than those reported to MSIS
only (20.1 %) (Table 2).
Representativeness
A response to the questionnaire was received from 16
laboratories, of which 15 perform diagnostic testing for
borrelia. Two assays for detection of IgM and IgG anti-
bodies were used by 14 (93 %) of the laboratories. How-
ever, the practice used for quantification and reporting of
Ig-levels differed between units and % of cut-off. The def-
inition of ‘high level IgG’ differed between laboratories
using the same diagnostic assay. Only one respondent was
positive to limit the number of different assays in use.
Seven respondents (44 %) were positive to implementing
uniform comments on laboratory reports, and 13 (81 %)
wanted a common assay-independent standard serum
specimens for calibration and quality assurance purposes.
Acceptability
Only 36 % of respondents indicated that the current noti-
fication criteria for LB were clear. Half of respondents
indicated that their respective laboratory had established
internal procedures or algorithms for determining which
LB cases should be notified to MSIS, based on laboratory
findings and clinical information. Three respondents com-
mented that in practice only neuroborreliosis is notified,
while one laboratory would notify all IgG positive speci-
mens to MSIS.
Discussion
This evaluation of the data quality, representativeness and
acceptability of the surveillance of LB through MSIS has
identified several strengths and weaknesses of the existing
system. Although no objectives have been developed ex-
plicitly for the surveillance of LB, perhaps the most im-
portant specific objective for MSIS in the context of LB is
to describe the incidence of infectious diseases over time,
Fig. 4 Results of linkage of Lyme borreliosis cases in the Norwegian Surveillance System for Communicable Diseases and the Norwegian Patient Registry
Table 2 Neuroborreliosis cases (neurological symptoms with peripheral nervous system manifestation or meningitis/encephalitis) by
source of data and diagnostic code, 2008-2012
Source Diagnosis code Neuroborreliosis Other clinical Missing clinical
NPR and MSIS Main diagnosis (n = 799) 609 (76.2 %) 132 (16.5 %) 58 (7.3 %)
Additional diagnosis (n = 223) 186 (83.4 %) 19 (8.5 %) 18 (8.1 %)
Possible diagnosis (n = 25) 24 (96.0 %) 0 (0 %) 1 8 (4.0 %)
MSIS only Not applicable (n = 358) 75 (20.1 %) 243 (67.9 %) 40 (11.2 %)
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including the geographic distribution and demographic
characteristics. Although not perfect, the data currently
collected does give an indication of areas of the country
where the disease is most prevalent. In addition, because
the current notification criteria have been in place since
1995, it is possible to make some conclusions regarding
trends over the last twenty years, assuming notification
practices have not changed. However, the results also indi-
cate that interpretation of the data collected using the
current notification criteria must be made with caution.
The major limitation of the current system is that there
are evident inconsistencies in what is being reported,
particularly from laboratories, indicating that the current
notification criteria are either not understandable or
intentionally not being followed.
The overall completeness of MSIS data was high, with
the exception of geographic location of exposure and
outcome of illness. The low completeness of the vari-
able “outcome of illness” was likely due to lack of
updated information. There is a long duration of illness
for some manifestations of the disease, and updated
information from the clinician is seldom available. Re-
ports originating from laboratories may not have the
necessary information to report outcome of illness. In
contrast, lack of completeness in geographic location of
exposure may have the following explanations: Firstly,
the patient may not know where they were infected,
particularly if they do not have any recollection of
being bitten by a tick. Secondly, the clinician may not
have asked the patient where they were infected.
Thirdly, the clinician did not notify the case to MSIS,
resulting in missing clinical information for multiple
variables, which has occurred for 10 % of cases. If MSIS
information is collected to describe the incidence of
infectious diseases over time, including the geographic
distribution and demographic characteristics, complete
information on place of infection is vital.
There are several findings that suggest that the validity
of some information in MSIS, in particular whether all
reported cases fulfill the notification criteria, is question-
able, although this was not specifically investigated as part
of this evaluation. Information on clinical symptoms,
which is a part of the notification criteria, is only reported
in free text in the physician’s notification form and the
coding of clinical presentation is done upon data entry
into MSIS. As the free-text information is not collected
systematically, it is not possible to determine whether all
cases reported meet the current case definition using the
free-text information. It is therefore not possible to deter-
mine the predictive positive value of notified cases as the
determination of whether a case has “clinically suspected
disseminated or chronic disease” is the responsibility of
the reporting clinician. As 15.9 % (n = 660) of cases
reported to MSIS are categorized as having a ‘other’ as
clinical presentation, this may indicate that many reported
cases present with symptoms that are not easily catego-
rized into one of the existing codes. A cursory review of
the free-text information suggests that for at least 12 of
the 256 cases reported in 2012 the clinical diagnosis of LB
was uncertain. Many of these patients have serological test
results that are consistent with either a current or previ-
ous LB infection but have ambiguous or diffuse symptoms
that may not be correctly attributed to LB. In addition, the
comparison of data from MSIS and NPR indicates that
the cases registered only in MSIS are unlike the cases reg-
istered in both MSIS and NPR, both in terms of age and
clinical presentation. Almost 80 % of cases in both MSIS
and NPR are registered as having neuroborreliosis com-
pared to just over 20 % of those in MSIS only, and are
younger than those cases registered in MSIS only.
In addition, there are a number of people who are
assigned diagnostic codes for LB in NPR that are ultim-
ately not reported to MSIS, including almost 4000 patients
who have A69.2 or M01.2 registered as a main diagnosis.
It is not unexpected that there are more patients regis-
tered with the ICD-10 code for LB than cases notified
through MSIS for several reasons. The ICD-10 codes used
in NPR are often assigned to patients while undergoing
diagnosis but may not ultimately reflect the final diagno-
sis. For this reason, patients in our analysis included those
who had been assigned one of the ICD-10 codes prede-
fined as possible Lyme borreliosis. These codes were pre-
selected in order to identify patients with compatible
symptoms that may not have been correctly assigned a
Lyme borreliosis-specific ICD-10 code. It was anticipated
that in most cases patients in NPR that have been assigned
the codes that were selected as possible LB diagnoses are
unlikely to be true LB cases. Nevertheless, given that 25
cases registered in MSIS had been registered in NPR with
one of these possible LB codes, it cannot be discounted
that some of the 7430 cases with possible LB ICD-10
codes in NPR are in fact true cases. The ICD-10 codes for
LD also include erythema migrans, which is not reportable
to MSIS. However, as NPR registers referrals or treat-
ments of patients to hospitals and specialists only, it is
unlikely that many of these cases presented with erythema
migrans only. An earlier study linking cases of tubercu-
losis in NPR and MSIS showed that there are many limita-
tions to how directly these data can be compared, partially
due to incorrect assignment of the ICD-10 codes in NPR
[14]. However, it is also possible that the significant
discrepancy between NPR and MSIS can be explained by
significant underreporting of cases that meet the notifica-
tion criteria. NPR coding also contributes towards hospital
reimbursement schemes, which may lead to a greater
incentive to register in NPR than in MSIS.
The representativeness of data in MSIS is also limited
due to the different testing procedures and reporting
MacDonald et al. BMC Public Health  (2016) 16:729 Page 8 of 11
practices at laboratories. As the case definition includes
laboratory test results, which the clinician must receive
before reporting the case, the laboratory plays a vital role
for surveillance. It is assumed that most notifications are
initiated by the laboratory, as laboratory-based surveil-
lance is the back-bone of the Norwegian notification sys-
tem. It is difficult to determine how big of an impact
differences in laboratory practices and use of different
assays have on describing the epidemiology of the
disease and on determining the geographical spread. It is
possible that in areas where the disease is common, the
representativeness is likely to be better as clinicians are
more familiar with the disease and are therefore more
likely to suspect the diagnosis and ensure appropriate
testing. Conversely, in areas where the disease is com-
mon clinicians may be more likely to assume LB is the
correct diagnosis in situations where the diagnosis is
equivocal. Regardless, the low acceptability is likely more
challenging to overcome for surveillance than the differ-
ences caused by the use of different assays, which can be
addressed by harmonizing how results are reported by
laboratories. The unclear and different use of diagnostic
cut-off values and interpretation of ‘high level IgG’ affect
algorithms for notification developed within laboratories
whereas the heterogenous reporting of results is prob-
lematic for the clinician who has to interpret the results
and for the patient. One means of accomplishing
harmonization is to develop standard text for reporting
and to establish standard cut-off values for antibody
levels and indexes. However, there is not consensus on
harmonization of thresholds or values for quantification.
Based on this information, it is apparent that there is a
need to improve the existing case definition in Norway.
However, there is no international consensus on the best
approach to LB surveillance and a number of different
approaches to LB surveillance are being used throughout
Europe. A 2010 survey found that 23 of 28 responding
European countries had surveillance systems in place for
LB, of which only 16 included mandatory reporting
requirements [9]. Some countries, as well as some fed-
eral states in Germany, require notification of erythema
migrans, as well as neuroborreliosis and Lyme arthritis
[15]. In France, a prospective study through a sentinel
network of general practitioners used a case definition
based on criteria developed by the European Concerted
Action on Lyme Borreliosis, which includes either the
presence of erythema migrans, or the appearance of
neurological, articular, cutaneous or cardiac symptoms
evocative of Lyme disease, in a patient with positive ser-
ology [16]. Other countries, like Norway, require notifi-
cation of disseminated infection only. In other countries,
such as Denmark, only neuroborreliosis is notifiable (a
confirmed case is a patient with clinical symptoms
consistent with Lyme neuroborreliosis and a positive
antibody index test, while a probable case is a patient
with clinical symptoms consistent with Lyme neurobor-
reliosis and borrelia antibodies in serum) [17]. Although
interest has been expressed in developing a common
European case definition to allow cross-national surveil-
lance and comparison between countries, the range of
surveillance methodologies and laboratory practices
across countries has so far made this an unworkable
proposition. In addition, there must be consensus on the
objectives of surveillance of LB before a common case
definition can be introduced. A European expert con-
sultation on surveillance of tick-borne diseases hosted
by the European Center for Disease Control concluded
that the unknown burden of disease associated with LB
is one of the primary incentives for establishment a
common case definition [9]. However, due to problems
of misdiagnosis and over-diagnosis, the surveillance of
LB should aim for specific rather than a sensitive system.
Particularly as the disease does not occur in outbreaks,
knowledge of each single case is not needed in order to
assess general trends. Nonetheless, geographical location
is an important aspect of the disease and data needs to
be collected at a sub-national level in order to accurately
follow trends, particularly in high-risk areas or new foci.
There are several options available to improve the no-
tification criteria for LB in Norway. The first option is to
maintain the existing notification criteria, but introduce
more specific requirements regarding the laboratory
results’ cut-offs and develop strategies for collecting suf-
ficient information to definitively categorize cases by
clinical presentation (in order to differentiate neurobor-
reliosis from other clinical manifestations). In order to
reliably distinguish neuroborreliosis cases from all other
Lyme borreliosis cases, it will be necessary to modify the
current notification criteria to define clear clinical and
laboratory criteria for reporting a neuroborreliosis case.
Although the categories currently used in MSIS give
some indication of the proportion of all cases that are
neuroborreliosis cases, the free-text information is cur-
rently insufficient to confirm whether a case is “clinically
compatible”, a determination that is at the discretion of
the reporting clinician. There are several other notifiable
diseases that are already reported separately to MSIS
depending on the clinical presentation and laboratory
diagnosis, such as Hepatitis B (for which acute and
chronic infection are reported separately). As Norway still
principally uses a paper-based system for notification,
adoption of an electronic form that allows for tailored
reporting for specific diseases may ease the systematic col-
lection of information on clinical presentation.
The second option is to make the criteria more sensi-
tive, by including erythema migrans. The added value
of receiving information on all cases of erythema
migrans is questionable, given the burden this would
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add on reporting clinicians. The third option is to make
the criteria more specific, by only requiring notification
of neuroborreliosis. Neuroborreliosis diagnosis is con-
sidered to improve validity of surveillance data as the
clinical picture is more specific and the laboratory
methods are more conclusive [9]. As knowledge of each
individual case is not needed to assess general trends, a
less sensitive but more acceptable system could lead to
better data validity. However, using these restrictive
notification criteria may produce a species-dependent
clinical picture. Some borrelia types are more com-
monly associated with neurological manifestations (B.
garinii and B. burdorferi ss), while B. afzelii is associ-
ated with acrodermatitis chronica atrophicans and Bor-
relia burgdorferi sensu stricto is more often associated
with arthritis [18]. All borrelia types are associated with
erythema migrans. The implications of only conducting
surveillance on one clinical presentation could mask
some unknown trends. In addition, burden of disease
would be more difficult to ascertain, although this is
already limitation of the current notification criteria, in
which erythema migrans alone is not notifiable. Given
the challenges with the surveillance of LB, there is no
gold standard for notification criteria. Any changes to
the notification criteria will need to be weighed against
the consequences of being unable to compare directly
with past data. With the existing weaknesses in the data
collected, changes to the notification criteria based on
sound evidence could lead to better quality data in the fu-
ture. The results of this evaluation support that it may be
advisable to change the Norwegian notification criteria,
particularly as the acceptability among laboratories is low.
The current notification criteria include some elements
which may lead to ambiguous cases, such as allowing for
IgM in serum. The notification criteria must be clear for
all users, particularly as the current notification criteria
are include both clinical and laboratory elements. It may
also be advantageous to ensure that the Norwegian notifi-
cation criteria are aligned with the EU case definitions [2],
in order to ease direct comparison with other countries in
the case that LB becomes notifiable in the European
region. Ultimately, the determination of the appropriate
notification criteria for Norway must be closely linked to
the purpose of the surveillance system.
Several studies are currently underway to determine
what changes would be most appropriate. A seropreva-
lence study is being conducted to describe regional
difference in antibody prevalence in the general popula-
tion in order to determine the pretest likelihood of a
positive result and to develop a common scale for semi-
quantitative reporting of results. A systematic review of
patient journals within NPR is also being conducted to
determine the validity of ICD-10 codes reported. This
will give an indication of how widely cases are
underreported and help determine whether cases reported
to MSIS fill the notification criteria. Other studies being
considered include a kit independent control to see how
much the results from different laboratories vary, as well
as an investigation of the acceptability of the notification
criteria among clinicians, as this information has currently
only been collected from laboratories.
Conclusions
The results of this evaluation suggest that there is a clear
need to review the current notification criteria in order
to ensure that they are unambiguous for clinicians and
laboratories. Given the challenges associated with sur-
veillance of LB, the selected notification criteria should
be closely linked with the purpose of the surveillance
system. Developing specific objectives for the surveil-
lance of LB may help guide this process. If the primary
objective of the system is to describe the incidence of
infectious diseases over time, including the geographic
distribution and demographic characteristics, restricting
reportable LB to neuroborreliosis may increase validity,
while a more sensitive case definition (potentially includ-
ing erythema migrans) may better reflect the true
burden of disease. Several key steps for improving
surveillance are to identify ways to harmonize notifiable
laboratory information and to identify strategies to
distinguish between neuroborreliosis and other clinical
manifestations. Any benefits associated with changing
the notification criteria will need to be weighed against
the consequences of limiting the comparability of future
surveillance data.
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